Form 4: Edwards Lifesciences CFO Scott B. Ullem Reports Changes in Beneficial Ownership

Sentiment:

SEC Form 4 Filing


CFO of Edwards Lifesciences, Scott B. Ullem, reports changes in beneficial ownership of company stock following a transaction on May 11, 2024.

Summary

  • On May 11, 2024, Scott B. Ullem, the CFO of Edwards Lifesciences, reported a transaction involving common stock.
  • 1,198 shares of common stock were disposed of at a price of $86.72.
  • Following the transaction, Ullem directly owns 30,561 shares of common stock.
  • Ullem also indirectly owns 266,318 shares through a trust.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors.

Key Dates

DateDescription
05/11/2024Date of the stock transaction.
05/13/2024Date of signature by Attorney-in-Fact.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.